Table 2.
Baseline characteristics by diastolic BP level
| Characteristic | Diastolic BP (mmHg) | P Value | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall (n=3474) | 35–59 (n=155) | 60–69 (n=591) | 70–79 (n=1129) | 80–89 (n=971) | 90–99 (n=450) | 100–139 (n=178) | ||
| Systolic BP (mmHg) | 136.2±19.8 | 119.6±19.1 | 124.8±16.6 | 131.6±16.1 | 139.1±15.9 | 150.3±16.4 | 166.2±21.5 | <0.001 |
| Diastolic BP (mmHg) | 78.8±12.4 | 55.0±4.3 | 65.1±3.0 | 74.6±3.0 | 83.6±2.9 | 93.8±2.9 | 107.6±7.6 | <0.001 |
| Age (yr) | 51.8±9.4 | 57.0±9.4 | 54.1±9.7 | 52.1±9.4 | 50.8±9.1 | 49.6±8.8 | 47.8±7.6 | <0.001 |
| Women | 1297 (37) | 71 (46) | 250 (42) | 394 (35) | 351 (36) | 160 (36) | 71 (40) | 0.01 |
| Nonwhite race | 817 (24) | 23 (15) | 109 (18) | 231 (20) | 258 (27) | 142 (32) | 54 (30) | <0.001 |
| County | ||||||||
| Brazil | 608 (18) | 2 (1) | 23 (4) | 87 (8) | 171 (18) | 176 (39) | 149 (84) | <0.001 |
| Canada | 388 (11) | 8 (5) | 56 (9) | 141 (12) | 135 (14) | 46 (10) | 2 (1) | |
| United States | 2478 (71) | 145 (94) | 512 (87) | 901 (80) | 665 (68) | 228 (51) | 27 (15) | |
| Graft vintage (yr) | 4.1 (1.7, 7.4) | 2.9 (1.2, 6.2) | 3.7 (1.6, 7.3) | 3.9 (1.6, 8.0) | 4.2 (1.8, 7.5) | 4.5 (2.1, 7.2) | 4.4 (1.9, 6.7) | 0.04 |
| History of CVD | 700 (20) | 56 (36) | 163 (28) | 208 (18) | 183 (19) | 64 (14) | 26 (15) | <0.001 |
| History of diabetes | 1392 (40) | 99 (64) | 304 (51) | 465 (41) | 361 (37) | 130 (29) | 33 (19) | <0.001 |
| BP-lowering medication use | ||||||||
| ACE inhibitors | 1127 (32) | 38 (25) | 190 (32) | 358 (32) | 306 (32) | 151 (34) | 84 (47) | <0.001 |
| Angiotensin receptor blockers | 464 (13) | 33 (21) | 95 (16) | 150 (13) | 125 (13) | 49 (11) | 12 (7) | <0.001 |
| β-Blockers | 1958 (56) | 106 (68) | 333 (56) | 600 (53) | 539 (56) | 271 (60) | 109 (61) | 0.002 |
| Calcium channel blockers | 1386 (40) | 66 (43) | 251 (42) | 498 (44) | 357 (37) | 162 (36) | 52 (29) | <0.001 |
| Diuretics | 1309 (38) | 77 (50) | 241 (41) | 413 (37) | 337 (35) | 168 (37) | 73 (41) | 0.004 |
| Any of the above | 3072 (88) | 141 (91) | 521 (88) | 996 (88) | 847 (87) | 402 (89) | 165 (93) | 0.31 |
| Number of BP-lowering medications used | 1.8±1.1 | 2.1±1.2 | 1.9±1.1 | 1.8±1.1 | 1.7±1.1 | 1.8±1.0 | 1.9±1.1 | <0.001 |
| BMI (kg/m2) | 29.1±6.2 | 29.4±7.3 | 29.1±6.2 | 29.2±6.2 | 29.3±6.2 | 29.0±5.8 | 28.4±5.2 | 0.51 |
| Current smoker | 384 (11) | 16 (10) | 52 (9) | 127 (11) | 101 (10) | 58 (13) | 30 (17) | 0.05 |
| Total cholesterol (mg/dl) | 185.0±44.1 | 176.9±40.3 | 176.1±41.7 | 181.6±44.1 | 188.0±42.0 | 193.8±43.4 | 204.1±56.6 | <0.001 |
| HDL cholesterol (mg/dl) | 46.2±13.9 | 44.1±14.0 | 47.0±14.4 | 46.1±13.8 | 46.3±13.9 | 46.0±13.6 | 46.7±14.2 | 0.32 |
| LDL cholesterol (mg/dl) | 101.3±34.5 | 93.5±33.2 | 93.6±32.4 | 98.6±33.3 | 103.3±33.1 | 109.6±34.4 | 118.5±45.6 | <0.001 |
| Triglycerides (mg/dl) | 199.3±188.4 | 215.1±167.5 | 183.6±112.5 | 203.0±271.7 | 201.8±133.8 | 199.2±126.5 | 201.7±140.2 | 0.32 |
| Urine ACR (mg/g) | ||||||||
| <10 | 1010 (29) | 56 (36) | 200 (34) | 364 (32) | 268 (28) | 93 (21) | 29 (16) | <0.001 |
| 10–29 | 908 (26) | 44 (28) | 181 (31) | 299 (26) | 243 (25) | 110 (24) | 31 (17) | |
| 30–299 | 1118 (32) | 35 (23) | 164 (28) | 350 (31) | 329 (34) | 164 (36) | 76 (43) | |
| ≥300 | 438 (13) | 20 (13) | 46 (8) | 116 (10) | 131 (13) | 83 (18) | 42 (24) | |
| eGFR (ml/min per 1.73 m2) | 48.9±17.6 | 46.5±18.1 | 47.9±17.3 | 49.2±17.3 | 49.2±17.8 | 50.2±18.1 | 47.8±16.8 | 0.14 |
| CKD stage (eGFR ml/min per 1.73 m2) | ||||||||
| 1T (≥90) | 96 (3) | 7 (5) | 15 (3) | 25 (2) | 29 (3) | 18 (4) | 2 (1) | 0.07 |
| 2T (60–89) | 723 (21) | 20 (13) | 120 (20) | 251 (22) | 204 (21) | 95 (21) | 33 (19) | |
| 3Ta (45–59)a | 1055 (30) | 42 (27) | 164 (28) | 353 (31) | 297 (31) | 135 (30) | 64 (36) | |
| 3Tb (30–44) | 1163 (33) | 59 (38) | 217 (37) | 356 (32) | 318 (33) | 159 (35) | 54 (30) | |
| 4T (15–29) | 428 (12) | 27 (17) | 74 (13) | 143 (13) | 118 (12) | 42 (9) | 24 (13) | |
| 5T (<15) | 9 (0) | 0 (0) | 1 (0) | 1 (0) | 5 (1) | 1 (0) | 1 (1) | |
Data reported as the mean±SD, median (25th percentile, 75th percentile), or frequency (%). P value comparisons across BP categories are based on the chi-squared test for categorical variables, Kruskal–Wallis test for median graft vintage, and ANOVA for other continuous variables. ACE, angiotensin enzyme-converting.
a
Terminology developed by Levey et al.40